Immunotherapy

Toxicities:

MHRA alert: Atezolizumab (Tecentriq) and other immune-stimulatory anti-cancer drugs: risk of severe cutaneous adverse reactions (SCARs) (June 2021) (www.gov.uk).

ATEZOLIZUMAB

Important: Therapy notes

MHRA advice: Atezolizumab (Tecentriq) and other immune-stimulatory anti-cancer drugs: risk of severe cutaneous adverse reactions (SCARs) (June 2021) (www.gov.uk).
NICE Guidance: Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer (June 2019) (www.nice.org.uk).


Risk minimisation materials

Important: Formulation and dosage details

Formulation:

Concentrate solution for infusion 840mg/14mL (hospital use only)

Dosage:

See SMC advice SMC2267, SMC2379, SMC2492

Important: Formulation and dosage details

Formulation:

Concentrate solution for infusion 1200mg/20mL (hospital use only)

Dosage:

See SMC advice 1336/18 and SMC2279SMC2349, SMC2379, SMC2492.

CEMIPLIMAB

Important: Therapy notes


Risk minimisation materials

Important: Formulation and dosage details

Formulation:

Solution for infusion 350mg (specialist use only)

Dosage:

See SMC advice 2216.

DURVALUMAB

Important: Therapy notes

Important: Formulation

Solution for infusion 50mg/ml (specialist use only)

IPILIMUMAB

Important: Therapy notes

Important: Formulation and dosage details

Formulation:

Concentrate for solution for infusion 5mg/mL (specialist use only)

Dosage:

See SMC advice 779/12, 997/14.

NIVOLUMAB

Important: Therapy notes

MHRA advice: Nivolumab (Opdivo): reports of cytomegalovirus (CMV) gastrointestinal infection or reactivation (October 2019) (www.gov.uk).
MHRA advice: Nivolumab (Opdivo). pembrolizumab (Keytruda): reports of organ transplant rejection (July 2017) (www.gov.uk).

Risk minimisation materials

Important: Formulation and dosage details

Formulation:

Concentrate for solution for infusion 10mg/mL (hospital use only)

Dosage:

First choice for indication as per SMC advice 2112.
See SMC advice 1120/16,  1180/16, 1240/17, 1261/17, 1188/16, 236223852394 and 2429.

Important: Formulation and dosage details

Formulation:

Solution for injection 40mg/4mL, 100mg/10mL (specialist use only)

Dosage:

See SMC advice 1144/16.

PEMBROLIZUMAB

Important: Therapy notes

MHRA advice: Nivolumab (Opdivo). pembrolizumab (Keytruda): reports of organ transplant rejection (July 2017) (www.gov.uk).

Risk management materials

Important: Formulation and dosage details

Formulation:

Concentrate for solution for infusion 25mg/mL (hospital use only)

Dosage:

See SMC advice 1239/17, 1291/18, 2144, 218722572247 and 2380.
See SMC advice 1086/15, 1204/17, 1239/171291/182144, 21872257 and 22472375 and 2420.